Original Articles
Copyright ©The Author(s) 2001.
World J Gastroenterol. Apr 15, 2001; 7(2): 228-234
Published online Apr 15, 2001. doi: 10.3748/wjg.v7.i2.228
Figure 1
Figure 1 HCV-RNA concentration (copies/mL) in sera from patients with chronic HCV infection with regard to HCV-RNA detectability in PBMC before, during and after an IFN-α therapy. The transition from detectable to non-detectable HCV-RNA in PBMC during drug therapy was associated with a strong and significantly decrease of serum HCV-RNA concentration. Vice versa, the transition from non-detectable to detectable HCV-RNA in PBMC, in the case of a breakthrough under therapy, or when therapy was stopped and a relapse was observed was associated with a marked and significantly increase of serum HCV-RNA concentration. Columns A and D: HCV-RNA concentration, if HCV-RNA in serum and in PBMC was detectable. Columns B and C: HCV-RNA concentration, if HCV-RNA in serum was detectable and in PBMC undetectable. (*) Test results less than 600 copies/mL are below the lower limit of quantification of the test and should be reported as “HCV detected, less than 600 copies/mL”.